SoftBank Group Formed a Joint Venture with Tempus. 


SoftBank Group has formed a joint venture with Tempus to improve Japan’s healthcare with AI.

Takeaway Points

  • SoftBank Group formed a joint venture with Tempus. 
  • The aim of the joint venture is to provide accurate medicine services and improve healthcare in Japan by using AI.
  • The company plans to partner with cancer genomic medicine hospitals, Japanese hospitals, medical facilities, etc. so as to help many people suffering from cancer.

Why did SoftBank Group enter into a joint venture agreement with Tempus?

SoftBank Group Corp. (TSE: 9984) announced on Thursday in Tokyo, Japan, that it has formed a joint venture “SB TEMPUS Corp.” with Tempus AI, Inc., a leader in artificial intelligence and precision medicine (NASDAQ: TEM, “Tempus”). The aim of the joint venture is to provide accurate medicine services and improve healthcare in Japan by using AI.

According to SBG, the agreement was entered into last month, and by July 2024, each of the companies will invest JPY15.0 billion in the venture, subject to closing conditions.

Masayoshi Son, Chairman and CEO of SBG, said that they are happy to enter into a joint venture agreement with Tempus to contribute to the improvement of healthcare in Japan.

“We are very pleased to establish a joint venture in Japan with Tempus to contribute to the advancement of healthcare. By promoting the advancing personalized medicine using AI, I strongly hope to reduce people’s sorrow and increase the happiness of as many people as possible,” Masayoshi said.

Eric Lefkofsky, Founder and CEO of Tempus, said in a comment that partnering with SBG helps them expand and bring their “AI-enabled solutions to the Japanese market.”.

“At Tempus, we are dedicated to transforming the landscape of precision medicine through the practical application of artificial intelligence. Partnering with SBG allows us to expand our reach and bring our AI-enabled solutions to the Japanese market. Together, we aim to ensure that patients benefit from personalized, data-driven therapies in an effort to help them live longer and healthier lives,” said Eric.

SB TEMPUS aims to leverage the expertise and technology that Tempus has developed to offer accurate medicine services like genetic testing, medical data collection and analysis, and AI-driven treatment proposals, according to the report. 

The company said it will partner with cancer genomic medicine hospitals, Japanese hospitals and medical facilities, pharmaceutical companies, biotech ventures, medical device companies, cancer insurance companies, and testing companies so as to help many people suffering from cancer. 

About SoftBank Group

The SoftBank Group invests in breakthrough technology to improve the quality of life for people around the world. The SoftBank Group is comprised of SoftBank Group Corp. (TOKYO: 9984), an investment holding company that includes stakes in AI, smart robotics, IoT, telecommunications, internet services, and clean energy technology providers, as well as a majority stake in Arm Holdings plc, which is building the future of computing; and the SoftBank Vision Funds and SoftBank Latin America Funds, which are investing more than US$160 billion to help extraordinary entrepreneurs transform industries and shape new ones.

About Tempus

Tempus is a technology company that advances precision medicine through the practical application of AI in healthcare. With one of the world’s largest multimodal data libraries and an operating system that makes data accessible and actionable, Tempus provides doctors with AI-powered precision medicine solutions. These solutions enable personalized treatment tailored to each patient’s condition and support the discovery, development, and delivery of optimal treatments. Additionally, Tempus offers doctors tools that learn from collecting more data, ensuring that each patient can benefit from the experiences of those treated before them.











Source link

Leave a Comment